Cytokinetics (CYTK) Set to Announce Quarterly Earnings on Wednesday

Cytokinetics (NASDAQ:CYTK) is set to issue its quarterly earnings data after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of ($1.16) per share for the quarter. Cytokinetics has set its FY 2024 guidance at EPS.Persons interested in participating in the company’s earnings conference call can do so using this link.

Cytokinetics (NASDAQ:CYTK) last issued its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.03) by ($0.35). The company had revenue of $1.70 million for the quarter, compared to the consensus estimate of $7.62 million. The company’s revenue was down 10.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.45) EPS. On average, analysts expect Cytokinetics to post $-5 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Cytokinetics Stock Performance

Cytokinetics stock opened at $65.05 on Tuesday. Cytokinetics has a 52-week low of $25.98 and a 52-week high of $110.25. The business has a 50-day simple moving average of $68.29 and a two-hundred day simple moving average of $61.41.

Insider Buying and Selling

In other Cytokinetics news, EVP Fady Ibraham Malik sold 32,605 shares of Cytokinetics stock in a transaction dated Tuesday, April 9th. The shares were sold at an average price of $74.31, for a total transaction of $2,422,877.55. Following the completion of the transaction, the executive vice president now owns 138,567 shares in the company, valued at $10,296,913.77. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, Director John T. Henderson sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 14th. The stock was sold at an average price of $76.48, for a total transaction of $382,400.00. Following the transaction, the director now directly owns 42,632 shares of the company’s stock, valued at approximately $3,260,495.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Fady Ibraham Malik sold 32,605 shares of the company’s stock in a transaction on Tuesday, April 9th. The shares were sold at an average price of $74.31, for a total transaction of $2,422,877.55. Following the completion of the transaction, the executive vice president now owns 138,567 shares of the company’s stock, valued at $10,296,913.77. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 80,771 shares of company stock valued at $5,689,675. Corporate insiders own 3.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Needham & Company LLC reissued a “buy” rating and issued a $108.00 price objective on shares of Cytokinetics in a research note on Tuesday, April 9th. Oppenheimer restated an “outperform” rating and issued a $107.00 price objective on shares of Cytokinetics in a report on Monday, March 4th. UBS Group cut shares of Cytokinetics from a “buy” rating to a “neutral” rating and increased their target price for the stock from $61.00 to $92.00 in a report on Wednesday, January 24th. Truist Financial restated a “buy” rating and issued a $86.00 price target on shares of Cytokinetics in a report on Monday, April 8th. Finally, HC Wainwright reiterated a “buy” rating and set a $94.00 price objective on shares of Cytokinetics in a research note on Wednesday, February 28th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $79.33.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.